NovoCure (NVCR) Research & Development (2014 - 2026)
NovoCure (NVCR) posted Research & Development of $61.7 million for Q2 2026, up 5.7% sequentially from $58.4 million in Q1 2026, and up 8.09% YoY from $57.1 million in Q2 2025.
NovoCure (NVCR) Research & Development (2014 - 2026) Analysis & Trends
NovoCure has reported Research & Development for 13 years, with the latest figure at $61.7 million in Q2 2026.
- Quarterly Research & Development rose 8.09% year-over-year to $61.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $247.2 million (up 2.98% YoY) and the FY2025 annual result came in at $240.1 million, changed 0.42% from the prior year.
- Research & Development climbed to $61.7 million in Q2 2026 per NVCR's latest filing, from $58.4 million in the prior quarter.
- Over five years, Research & Development peaked at $68.7 million in Q4 2025 and troughed at $42.2 million in Q1 2022.
- A 5-year average of $57.7 million and a median of $58.0 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2023: Research & Development slipped 8.02% in 2022, then jumped 41.36% in 2023.
- Over 5 years, Research & Development stood at $54.8 million in 2022, then advanced by 5.9% to $58.1 million in 2023, then advanced by 16.12% to $67.4 million in 2024, then increased by 1.85% to $68.7 million in 2025, then dropped by 10.16% to $61.7 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $61.7 million, $58.4 million, and $68.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.24 Bn | 193.64 Bn | 7.27 Bn | 892.00 Mn |
| 2 | Stryker | 128.63 Bn | 125.15 Bn | 4.50 Bn | 434.00 Mn |
| 3 | Medtronic | 119.19 Bn | 109.97 Bn | 6.41 Bn | 671.00 Mn |
| 4 | Boston Scientific | 73.51 Bn | 72.97 Bn | 3.85 Bn | 554.00 Mn |
| 5 | Edwards Lifesciences | 52.11 Bn | 47.85 Bn | 1.35 Bn | 278.90 Mn |
| 6 | Dexcom | 34.64 Bn | 32.70 Bn | 830.00 Mn | 153.00 Mn |
| 7 | GE HealthCare Technologies | 34.01 Bn | 31.90 Bn | 2.18 Bn | 323.00 Mn |
| 8 | Koninklijke Philips | 26.40 Bn | 23.08 Bn | 4.55 Bn | -562.58 Mn |
| 9 | Steris | 23.14 Bn | 22.65 Bn | 684.20 Mn | 28.60 Mn |
| 10 | NovoCure | 2.04 Bn | 1.60 Bn | 142.48 Mn | 61.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.68 Mn |
| Mar 31, 2026 | 58.36 Mn |
| Dec 31, 2025 | 68.66 Mn |
| Sep 30, 2025 | 58.55 Mn |
| Jun 30, 2025 | 57.07 Mn |
| Mar 31, 2025 | 55.79 Mn |
| Dec 31, 2024 | 67.41 Mn |
| Sep 30, 2024 | 59.83 Mn |
| Jun 30, 2024 | 56.62 Mn |
| Mar 31, 2024 | 55.21 Mn |
| Dec 31, 2023 | 58.06 Mn |
| Sep 30, 2023 | 57.96 Mn |
| Jun 30, 2023 | 58.49 Mn |
| Mar 31, 2023 | 59.70 Mn |
| Dec 31, 2022 | 54.82 Mn |
| Sep 30, 2022 | 51.96 Mn |
| Jun 30, 2022 | 57.08 Mn |
| Mar 31, 2022 | 42.23 Mn |
| Dec 31, 2021 | 56.93 Mn |
| Sep 30, 2021 | 48.14 Mn |